Ittaman Sunitha V, VanWormer Jeffrey J, Rezkalla Shereif H
Department of Internal Medicine, Marshfield Clinic, Marshfield, WI USA.
Epidemiology Research Center, Marshfield Clinic Research Foundation, Marshfield, WI USA.
Clin Med Res. 2014 Dec;12(3-4):147-54. doi: 10.3121/cmr.2013.1197. Epub 2014 Feb 26.
Aspirin therapy is well-accepted as an agent for the secondary prevention of cardiovascular events and current guidelines also define a role for aspirin in primary prevention. In this review, we describe the seminal trials of aspirin use in the context of current guidelines, discuss factors that may influence the effectiveness of aspirin therapy for cardiovascular disease prevention, and briefly examine patterns of use. The body of evidence supports a role for aspirin in both secondary and primary prevention of cardiovascular events in selected population groups, but practice patterns may be suboptimal. As a simple and inexpensive prophylactic measure for cardiovascular disease, aspirin use should be carefully considered in all at-risk adult patients, and further measures, including patient education, are necessary to ensure its proper use.
阿司匹林疗法作为心血管事件二级预防的药物已被广泛接受,当前指南也明确了阿司匹林在一级预防中的作用。在本综述中,我们根据当前指南描述阿司匹林使用的开创性试验,讨论可能影响阿司匹林预防心血管疾病疗效的因素,并简要审视其使用模式。证据支持阿司匹林在特定人群的心血管事件二级和一级预防中发挥作用,但实际使用模式可能并不理想。作为一种简单且廉价的心血管疾病预防措施,应在所有有风险的成年患者中仔细考虑使用阿司匹林,并且需要采取包括患者教育在内的进一步措施以确保其正确使用。